Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Trial Profile

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2019 According to a Roswell Park Cancer Institute media release, AIM ImmunoTech Inc. has agreed to provide rintatolimod for this study.
    • 17 Jun 2019 According to a Hemispherx Biopharma media release, two patients have been enrolled and both are in early treatment.
    • 02 Apr 2019 According to a Hemispherx Biopharma media release, Dr. Pawel Kalinski are the lead investigators of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top